Cargando…
Pluripotent Stem Cell-Based Drug Screening Reveals Cardiac Glycosides as Modulators of Myotonic Dystrophy Type 1
There is currently no treatment for myotonic dystrophy type 1 (DM1), the most frequent myopathy of genetic origin. This progressive neuromuscular disease is caused by nuclear-retained RNAs containing expanded CUG repeats. These toxic RNAs alter the activities of RNA splicing factors, resulting in al...
Autores principales: | Maury, Yves, Poydenot, Pauline, Brinon, Benjamin, Lesueur, Lea, Gide, Jacqueline, Roquevière, Sylvain, Côme, Julien, Polvèche, Hélène, Auboeuf, Didier, Alexandre Denis, Jérome, Pietu, Geneviève, Furling, Denis, Lechuga, Marc, Baghdoyan, Sandrine, Peschanski, Marc, Martinat, Cécile |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327858/ https://www.ncbi.nlm.nih.gov/pubmed/30639849 http://dx.doi.org/10.1016/j.isci.2018.12.019 |
Ejemplares similares
-
Pluripotent Stem Cells in Disease Modeling and Drug Discovery for Myotonic Dystrophy Type 1
por: Bérenger-Currias, Noémie, et al.
Publicado: (2023) -
MBNL‐dependent impaired development within the neuromuscular system in myotonic dystrophy type 1
por: Tahraoui‐Bories, Julie, et al.
Publicado: (2023) -
Expression of miRNAs from the Imprinted DLK1/DIO3 Locus Signals the Osteogenic Potential of Human Pluripotent Stem Cells
por: Barrault, Laetitia, et al.
Publicado: (2019) -
Cells of Matter—In Vitro Models for Myotonic Dystrophy
por: Matloka, Magdalena, et al.
Publicado: (2018) -
SISTEMA: A large and standardized collection of transcriptome data sets for human pluripotent stem cell research
por: Jarrige, Margot, et al.
Publicado: (2021)